BioCentury | Mar 24, 2016
Distillery Therapeutics

Therapeutics: Interleukin-1 receptor

...anti-inflammatory compounds to treat bacterial airway infections in CF and other diseases. Amgen Inc. , Crealta Pharmaceuticals LLC...
BioCentury | Jan 20, 2014
Company News

Crealta Pharmaceuticals, Savient deal

...pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million (see BioCentury, Dec.16, 2013). Crealta Pharmaceuticals LLC...
BioCentury | Dec 16, 2013
Company News

Crealta Pharmaceuticals, Savient deal

...uricase), for the nine months ended Sept. 30 (see BioCentury, Aug. 12 & Oct. 21). Crealta Pharmaceuticals LLC...
BioCentury | Dec 12, 2013
Company News

Crealta to acquire Savient assets

Crealta Pharmaceuticals LLC (Lake Forest, Ill.) will acquire the pharmaceutical portfolio of Savient Pharmaceuticals Inc. (OTCQB:SVNTQ), including gout drug Krystexxa pegloticase, for about $120.4 million. The deal is the first for Crealta, which debuted in...
BioCentury | Aug 12, 2013
Company News

Crealta Pharmaceuticals Inc., GTCR LLC pharmaceuticals news

...front, plus warrants and up to $50 million in revenue-dependent milestones (see BioCentury, May 6). Crealta Pharmaceuticals...
Items per page:
1 - 5 of 5
BioCentury | Mar 24, 2016
Distillery Therapeutics

Therapeutics: Interleukin-1 receptor

...anti-inflammatory compounds to treat bacterial airway infections in CF and other diseases. Amgen Inc. , Crealta Pharmaceuticals LLC...
BioCentury | Jan 20, 2014
Company News

Crealta Pharmaceuticals, Savient deal

...pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million (see BioCentury, Dec.16, 2013). Crealta Pharmaceuticals LLC...
BioCentury | Dec 16, 2013
Company News

Crealta Pharmaceuticals, Savient deal

...uricase), for the nine months ended Sept. 30 (see BioCentury, Aug. 12 & Oct. 21). Crealta Pharmaceuticals LLC...
BioCentury | Dec 12, 2013
Company News

Crealta to acquire Savient assets

Crealta Pharmaceuticals LLC (Lake Forest, Ill.) will acquire the pharmaceutical portfolio of Savient Pharmaceuticals Inc. (OTCQB:SVNTQ), including gout drug Krystexxa pegloticase, for about $120.4 million. The deal is the first for Crealta, which debuted in...
BioCentury | Aug 12, 2013
Company News

Crealta Pharmaceuticals Inc., GTCR LLC pharmaceuticals news

...front, plus warrants and up to $50 million in revenue-dependent milestones (see BioCentury, May 6). Crealta Pharmaceuticals...
Items per page:
1 - 5 of 5